The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
May 22, 2017
View Complete Issue         Table of Contents 2019 
Vonvendi - Recombinant von Willebrand Factor (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Vonvendi - Recombinant von Willebrand Factor (online only)
May 22, 2017 (Issue: 1521)
The FDA has approved intravenously administered recombinant von Willebrand factor (Vonvendi - Shire) for adults with von Willebrand disease (VWD) who require on-demand treatment and control of bleeding episodes. It is the first recombinant von...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Vonvendi - Recombinant von Willebrand Factor (online only)
Article code: 1521f
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.